⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Abstract

The findings of this study indicated that (64)Cu-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.